Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
AssigneeGilead Sciences, Inc.
InventorsLuiz Belardinelli, Hongyan Zhong, Dewan Zeng
Life of this patent
Estimating the term…
Abstract
Provided are methods of improving the cardiac condition of post-myocardial infarction (MI) patients and reducing cardiovascular death and hospitalization due to heart failure or arrhythmias, by administering a therapeutically effective amount of an A2B adenosine receptor antagonist.
Claims29
A method of treating heart failure and/or arrhythmia in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
A method of reducing the progression of heart failure in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
A method of reducing arrhythmia in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
A method of reducing the incidence of sudden cardiac death in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
A method of increasing the left ventricle ejection fraction (LVEF) in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
A method of inhibiting left ventricle enlargement in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
A method of reducing left ventricle end systolic volume in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
A method of reducing left ventricle end diastolic volume in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
A method of ameliorating left ventricle dysfunction in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
A method of improving myocardial contractibility in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
A method of reducing the release of IL-6, TNFa, BNP, or ST2 (suppression of tumorigenicity 2) from a cardiac cell in a patient that has suffered myocardial infarction (MI), comprising administering to the patient a therapeutically effective amount of an A2B adenosine receptor antagonist.
Dependencies are inferred from the claim text.